-
Health Canada Issues Anaphylaxis Warning for MS Drug
03 Sep 2025 20:15 GMT
… that patients taking glatiramer acetate could experience … glatiramer acetate products. Some cases “required treatment with epinephrine and other appropriate medical … interventions,” but none of the Canadian cases were fatal.
The glatiramer …
-
Gaps in Observational Data Challenge Understanding of Infection Risk in MS Treatments
23 Aug 2025 19:43 GMT
… -modifying treatments (DMTs).1 Although clinical trials have … compared with randomized trial data.
The Multiple … and Amsterdam University Medical Center analyzed observational … therapies, including interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod …
-
Direct-to-Consumer Pharmacies May Reduce Total Prescription Price for Neurological Medication
21 Aug 2025 01:30 GMT
… pharmacies could reduce total prescription drug medication costs but not out-of … Plus Drug Company with commercial insurance plan costs of various neurological medications … For DTC, the most expensive medications were glatiramer acetate ($24 186), fingolimod …
-
Genetic Biomarker Predicts Optimal Treatment for Multiple Sclerosis
13 Aug 2025 09:38 GMT
… clear criterion for choosing the medication.
The international research group has … targeted further development of the drug.
Reference: Zhang BC, Schneider- … as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis …
-
Christina Applegate hospitalized: Inside her double kidney infection amid MS struggles (symptoms, risk factors, treatment)
06 Aug 2025 05:25 GMT
… right kidney to her left. Doctors initially suspected a urinary tract … and improving quality of life. Treatment approaches include disease-modifying therapies … include interferon-beta and glatiramer acetate.Oral medications: Examples include dimethyl fumarate …
-
Global Multiple Sclerosis Treatment Market To Reach $31.55 Billion By 2029 With A Growth Rate Of 4.8%.
01 Jul 2025 10:56 GMT
… S.A., Mallinckrodt Pharmaceuticals, Acorda Therapeutics Inc., Adamas Pharmaceuticals Inc., Mapi Pharma …
3 By Symptomatic Treatments: Muscle Relaxants, Antidepressants, Anticonvulsants, Bladder Dysfunction Drugs
4 By …
-
Multiple Sclerosis Clinical Trial Pipeline Shows Potential with Active Contributions from 60+ Key Companies | DelveInsight
24 Jun 2025 17:00 GMT
… medications to improve the treatment landscape.
Promising pipeline multiple sclerosis treatment drugs … and glatiramer acetate … trial (NCT03232073) showed that treatment with Ponesimod (Vanda Pharmaceuticals … Biohaven Pharmaceuticals, HuniLife Biotechnology, …
-
Multiple Sclerosis Clinical Trial Pipeline Shows Potential With Active Contributions From 60+ Key Companies Delveinsight
24 Jun 2025 17:19 GMT
… medications to improve the treatment landscape. Promising pipeline multiple sclerosis treatment drugs … and glatiramer acetate … trial (NCT03232073) showed that treatment with Ponesimod (Vanda Pharmaceuticals … Biohaven Pharmaceuticals, HuniLife Biotechnology, …
-
Copaxone, Glatopa (glatiramer acetate): Drug Safety Communication - FDA Adds Boxed Warning About a Rare but Serious Allergic Reaction Called Anaphylaxis
22 Jan 2025 21:22 GMT
… " below.
BACKGROUND: Glatiramer acetate is an FDA-approved medicine to treat patients … occur at any point during glatiramer acetate treatment, including years after starting … ;22/2025 - Drug Safety Communication - FDA]
Content current as …
-
Copaxone, Glatopa (glatiramer acetate): Drug Safety Communication - FDA Adds Boxed Warning About a Rare but Serious Allergic Reaction Called Anaphylaxis
22 Jan 2025 21:44 GMT
… " below.
BACKGROUND: Glatiramer acetate is an FDA-approved medicine to treat patients … occur at any point during glatiramer acetate treatment, including years after starting … ;22/2025 - Drug Safety Communication - FDA]
Content current as …
About
© 1995-2025